
John Nesnas - Medical Director - International Developed …
John is a highly accomplished pharmaceutical professional with extensive experience in strategic leadership, medical affairs, and quality management. Currently serving as a regional Medical Lead...
- 职位: Medical Director || Regional …
- 位置: Pfizer
- 500+ 连接数
John NESNAS | Medical Advisor | Inflammation and Immunology
John NESNAS, Medical Advisor | Cited by 44 | | Read 4 publications | Contact John NESNAS
Risk of Melanoma and Nonmelanoma Skin Cancer in People with …
Electronic address: [email protected]. Although genetic studies have found an inverse relationship between vitiligo and skin cancer, epidemiological evidence is conflicting.
Risk of Melanoma and Nonmelanoma Skin Cancer in People with …
2022年12月13日 · In this study, we set out to assess the risk of melanoma and NMSC in people with vitiligo compared with that in people without the condition in a large population representative of United Kingdom−based cohort.
Caution Required in Interpreting Primary Care Vitiligo Skin
2023年11月23日 · John Ferguson 1 , Viktoria Eleftheriadou 2 , John Nesnas 3 Affiliations 1 St John's Institute of Dermatology, Guys and St Thomas' Hospital, London, United Kingdom.
2023年5月3日 · John Ferguson1, Viktoria Eleftheriadou2 and John Nesnas3 Although genetic studies have found an inverse relationship between vitiligo and skin cancer, epidemiological evidence is conflicting. We investigated the risk of skin cancer in …
RISK OF MELANOMA AND NON-MELANOMA SKIN CANCER IN
2023年5月1日 · Translational research has revealed key mechanisms of disease, including cellular stress, innate immune activation, T cell–mediated elimination of melanocytes from the skin resulting in clinically apparent white spots, as well as stem cell regeneration that reverses established lesions.
Real-World Budget Impact of Fidaxomicin versus Vancomycin or ...
2023年1月6日 · Support for J.N. was provided by Astellas Europe as part of an investigator-initiated study. Fidaxomicin, a macrocyclic antibiotic, selectively kills Clostridioides difficile and reduces C. difficile infection (CDI) recurrence compared with vancomycin, but some studies and guidelines report fidaxomicin as being less cost-effective.
John Nesnas's research works | University College London …
John Nesnas's 4 research works with 1 citations and 31 reads, including: Efficacy and Safety of Abrocitinib Monotherapy in Adolescents and Adults: A Post Hoc Analysis of the Phase 3...
Articles by John Nesnas’s Profile | NCBI - National Center for ...
Articles by John Nesnas on Muck Rack. Find John Nesnas's email address, contact information, LinkedIn, Twitter, other social media and more.